OTLK

Outlook Therapeutics, Inc. Common Stock

0.66

USD

-0.01

-0.89%

Sep 24, 15:59 UTC -4

Closed

Pre-Market

0.67

+0.01

+1.71%

Outlook Therapeutics, Inc. Common Stock Profile

About

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

Info & Links

CEO

Robert C. Jahr

Headquarters

111 S. WOOD AVENUE, UNIT #100
ISELIN, NJ 08852, UNITED STATES

Auditor

KPMG LLP

Share holders

Employees

Outlook Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

162.38M

Enterprise Value

169.36M

Enterprise Value/EBITDA(ttm)

-3.05

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

272.20%

Operating Margin(ttm)

Profit Margin(ttm)

-55164.46%

Return on Equity(ttm)

Return on Invested Capital(ttm)

321.55%

Return on Assets(ttm)

-254.82%

Income Statement

Revenue(ttm)

-1.16M

Revenue Per Share(ttm)

-0.00

Gross Profit(ttm)

-2.28M

EBITDA(ttm)³

-55.53M

Net Income Available to Common(ttm)

-61.12M

Diluted EPS(ttm)

-0.77

Share Statistics

Beta (5Y Monthly)

0.74

52-Week Change

-33.66%

S&P 500 52-Week Change

19.38%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

243.45M

Dividend Yield

0.00%

Float⁴

239.07M

% Held by Insiders

1.80%

% Held by Institutions

11.20%

Balance Sheet

Total Cash(mrq)

11.24M

Total Cash Per Share(mrq)

0.05

Total Debt(mrq)

18.23M

Total Debt/Equity(mrq)

-175.39%

Current Ratio(mrq)

0.81%

Quick Ratio(mrq)

0.63%

Book Value Per Share(mrq)

-0.06

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.32

Free Cash Flow(ytd)

-43.78M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.